Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
- PMID: 25057166
- DOI: 10.1093/annonc/mdu275
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Erratum in
-
Corrections to "Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features".Ann Oncol. 2015 Feb;26(2):445. doi: 10.1093/annonc/mdu548. Epub 2020 Jan 7. Ann Oncol. 2015. PMID: 32590893 No abstract available.
Abstract
Background: Differences exist between the proximal and distal colon in terms of developmental origin, exposure to patterning genes, environmental mutagens, and gut flora. Little is known on how these differences may affect mechanisms of tumorigenesis, side-specific therapy response or prognosis. We explored systematic differences in pathway activation and their clinical implications.
Materials and methods: Detailed clinicopathological data for 3045 colon carcinoma patients enrolled in the PETACC3 adjuvant chemotherapy trial were available for analysis. A subset of 1404 samples had molecular data, including gene expression and DNA copy number profiles for 589 and 199 samples, respectively. In addition, 413 colon adenocarcinoma from TCGA collection were also analyzed. Tumor side-effect on anti-epidermal growth factor receptor (EGFR) therapy was assessed in a cohort of 325 metastatic patients. Outcome variables considered were relapse-free survival and survival after relapse (SAR).
Results: Proximal carcinomas were more often mucinous, microsatellite instable (MSI)-high, mutated in key tumorigenic pathways, expressed a B-Raf proto-oncogene, serine/threonine kinase (BRAF)-like and a serrated pathway signature, regardless of histological type. Distal carcinomas were more often chromosome instable and EGFR or human epidermal growth factor receptor 2 (HER2) amplified, and more frequently overexpressed epiregulin. While risk of relapse was not different per side, SAR was much poorer for proximal than for distal stage III carcinomas in a multivariable model including BRAF mutation status [N = 285; HR 1.95, 95% CI (1.6-2.4), P < 0.001]. Only patients with metastases from a distal carcinoma responded to anti-EGFR therapy, in line with the predictions of our pathway enrichment analysis.
Conclusions: Colorectal carcinoma side is associated with differences in key molecular features, some immediately druggable, with important prognostic effects which are maintained in metastatic lesions. Although within side significant molecular heterogeneity remains, our findings justify stratification of patients by side for retrospective and prospective analyses of drug efficacy and prognosis.
Keywords: colon cancer; expression profiling; mutations; oncogenic pathways; survival.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.J Natl Cancer Inst. 2016 Dec 31;109(5):djw272. doi: 10.1093/jnci/djw272. Print 2017 May. J Natl Cancer Inst. 2016. PMID: 28040692 Free PMC article. Clinical Trial.
-
Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.Br J Cancer. 2015 Sep 15;113(6):979-88. doi: 10.1038/bjc.2015.296. Epub 2015 Aug 25. Br J Cancer. 2015. PMID: 26305864 Free PMC article.
-
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.JAMA Oncol. 2018 Jul 12;4(7):e173695. doi: 10.1001/jamaoncol.2017.3695. Epub 2018 Jul 12. JAMA Oncol. 2018. PMID: 29167892 Free PMC article.
-
Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.Discov Med. 2016 May;21(117):341-7. Discov Med. 2016. PMID: 27355330 Review.
-
Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature.Anticancer Res. 2017 Dec;37(12):6563-6574. doi: 10.21873/anticanres.12113. Anticancer Res. 2017. PMID: 29187431 Review.
Cited by
-
Right-sided versus left-sided colorectal cancer in elderly patients: a sub-analysis of a large multicenter case-control study in Japan.Surg Today. 2024 Jun 5. doi: 10.1007/s00595-024-02827-9. Online ahead of print. Surg Today. 2024. PMID: 38839654
-
Prognostic factors and survival disparities in right-sided versus left-sided colon cancer.Sci Rep. 2024 May 29;14(1):12306. doi: 10.1038/s41598-024-63143-3. Sci Rep. 2024. PMID: 38811769 Free PMC article.
-
Unraveling the Interplay of KRAS, NRAS, BRAF, and Micro-Satellite Instability in Non-Metastatic Colon Cancer: A Systematic Review.Diagnostics (Basel). 2024 May 12;14(10):1001. doi: 10.3390/diagnostics14101001. Diagnostics (Basel). 2024. PMID: 38786299 Free PMC article. Review.
-
RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification.Sci Rep. 2024 May 19;14(1):11432. doi: 10.1038/s41598-024-62096-x. Sci Rep. 2024. PMID: 38763942 Free PMC article.
-
Distinct Driver Pathway Enrichments and a High Prevalence of TSC2 Mutations in Right Colon Cancer in Chile: A Preliminary Comparative Analysis.Int J Mol Sci. 2024 Apr 25;25(9):4695. doi: 10.3390/ijms25094695. Int J Mol Sci. 2024. PMID: 38731914 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous